Suppr超能文献

住院患者与秋水仙碱相关的未识别致死病例。

Unrecognized fatalities related to colchicine in hospitalized patients.

机构信息

Division of Emergency Medicine, Washington University, Saint Louis, MO 63110, USA.

出版信息

Clin Toxicol (Phila). 2011 Aug;49(7):648-52. doi: 10.3109/15563650.2011.589844. Epub 2011 Jul 8.

Abstract

BACKGROUND

Colchicine is commonly used for the treatment of gout and occasionally for other inflammatory diseases. It has a narrow therapeutic index and the potential for severe or fatal toxicity.

OBJECTIVES

We sought to determine (1) the frequency of colchicine toxicity among hospitalized patients taking colchicine who died during an admission, (2) the likelihood that colchicine contributed to death, (3) whether patients were taking interacting medications that could have contributed to toxicity, and (4) whether colchicine dosing among these patients adhered to established guidelines.

METHODS

We conducted an IRB-approved, retrospective chart review at an urban, tertiary care, 1228-bed, university hospital. Subjects included hospitalized patients who received colchicine and died in hospital between 1 January 2000 and 28 February 2007. We reviewed charts for signs and symptoms of colchicine toxicity. An expert panel reviewed each case and classified the likelihood of colchicine toxicity, the likelihood of a causal role of colchicine in the death using the WHO classification system, and the appropriateness of colchicine dosing.

RESULTS

Thirty-seven hospitalized patients who died during the 86-month study period received colchicine. Toxicity was unlikely in 20/37, possible in 8/37, likely in 5/37, and certain in 4/37. A contributing role for colchicine in causing death was unlikely in 24/37, possible in 7/37, likely in 3/37, and certain in 3/37. Colchicine doses (based on creatinine clearance) exceeded the accepted range for 12 patients, including 10 of 17 cases of toxicity and 8 of 13 cases of death classified as possible or higher. Seventeen patients received interacting medications, including 8 of 17 cases of toxicity and 8 of 13 cases of death classified as possible or higher.

CONCLUSION

Colchicine toxicity was frequent in this cohort and may have contributed to about one-third of the deaths. Inappropriate dosing of colchicine occurred frequently and was related to toxicity and death.

摘要

背景

秋水仙碱常用于治疗痛风,偶尔也用于治疗其他炎症性疾病。它的治疗指数较窄,有发生严重或致命毒性的风险。

目的

我们旨在确定(1)在住院期间接受秋水仙碱治疗且死亡的患者中,秋水仙碱中毒的发生频率;(2)秋水仙碱导致死亡的可能性;(3)患者是否正在服用可能导致毒性的相互作用药物;(4)这些患者的秋水仙碱给药剂量是否符合既定指南。

方法

我们在一家城市三级保健、1228 张床位的大学附属医院进行了一项经机构审查委员会批准的回顾性病历审查。研究对象包括 2000 年 1 月 1 日至 2007 年 2 月 28 日期间住院并在院内死亡且接受过秋水仙碱治疗的患者。我们查阅病历以了解秋水仙碱中毒的体征和症状。一个专家小组审查了每个病例,并根据世界卫生组织分类系统,对秋水仙碱中毒的可能性、秋水仙碱在死亡中的因果作用的可能性以及秋水仙碱给药的适宜性进行分类。

结果

在 86 个月的研究期间,37 名住院死亡患者接受了秋水仙碱治疗。毒性不太可能的有 20/37,可能的有 8/37,很可能的有 5/37,确定的有 4/37。秋水仙碱在导致死亡中的作用不太可能的有 24/37,可能的有 7/37,很可能的有 3/37,确定的有 3/37。根据肌酐清除率,12 名患者的秋水仙碱剂量超过了可接受范围,其中 10 例毒性病例和 13 例死亡分类为可能或更高的病例中包括 8 例。17 名患者接受了相互作用药物,其中 8 例毒性病例和 13 例死亡分类为可能或更高的病例中包括 8 例。

结论

在本队列中,秋水仙碱中毒很常见,可能导致约三分之一的死亡。秋水仙碱剂量不当的情况很常见,与毒性和死亡有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验